← Leaderboards
Alfred L. Garfall
University Of Pennsylvania
$2,897,857
Attributed
$15,267,399
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.3M · FY2020–25$5M$3.8M$2.5M$1.3M$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$15,267,399 · 2
By mechanism
U01$14,843,451 · 1
R21$423,948 · 1
Top collaborators
- Vijay Bhoj5 shared
- Carl H. June5 shared
- James F Markmann5 shared
- Michael C. Milone5 shared
- Ali Naji5 shared
Most similar at University Of Pennsylvania
Same institution · by research overlap
- David Seth Goldberg$7,222,905
- Steven Mark Albelda$22,046,338
- Robert A. Eisenberg$5,606,093
- Vijay Bhoj$3,391,776
- Ali Naji$46,943,355
Others in their field
Other Emerging Leaders on “Refractory”
- John Damon Chodera · Sloan-Kettering Inst Can Research$13,706,419
- Leonard Freedman · Leidos Biomedical Research, Inc.$9,392,562
- Christopher B. Granger · Duke University$9,106,303
- Crystal Mackall · Children'S Hosp Of Philadelphia$8,791,590
- Steven Armen Boyd · Venatorx Pharmaceuticals, Inc.$6,328,779
- Patricio Sepulveda · Amplo Biotechnology, Inc.$5,506,739
Research focus
RefractoryCd19 GeneInnovationPlasma CellsMultiple MyelomaMalignant NeoplasmsEngineered T CellsImmunotherapyIn VivoPhenotypeT-LymphocyteT Cell TherapyAntigensClinical TrialsB-LymphocytesCellsCell TherapyImmunityChimeric Antigen Receptor T CellsClinically SignificantBiologyCell MaturationAntibody ResponseAllografting
Grant awards (6)
Autologous chimeric antigen receptor engineered T cell immunotherapy for desensitization in patients awaiting kidney transplantation$4,303,502
U01 · FY2025 · AI
Autologous chimeric antigen receptor engineered T cell immunotherapy for desensitization in patients awaiting kidney transplantation$3,825,129
U01 · FY2024 · AI
Autologous chimeric antigen receptor engineered T cell immunotherapy for desensitization in patients awaiting kidney transplantation$764,364
U01 · FY2023 · AI
Autologous chimeric antigen receptor engineered T cell immunotherapy for desensitization in patients awaiting kidney transplantation$2,975,228
U01 · FY2022 · AI
Autologous chimeric antigen receptor engineered T cell immunotherapy for desensitization in patients awaiting kidney transplantation$2,975,228
U01 · FY2021 · AI
Anti-Sox2 immunotherapy to prevent multiple myeloma relapse$423,948
R21 · FY2020 · CA · contact PI